We're looking for the fiercest women in biotech

FierceBiotech's "10 Top Women in Biotech" report honors top innovators, dealmakers and other standouts in life sciences. And we have opened our online form for nominating women for this year's feature. Submit your nominations here.

Too few women rise to senior roles in the biopharma industry, making the accomplishments of top female executives truly exceptional. Former Millennium chief Deborah Dunsire, who was named to her second CEO job at EnVivo Pharmaceuticals in July, told me earlier this year that you at least need both hands and both feet to count all the female CEOs now--and you used to need only one hand.

Back in 2010, we noted that in an entrepreneurial industry like biotech, results matter most. So, in some ways, it's the ideal climate for women who want to reach the top ranks of business. Each of the women we highlight annually exemplifies this assertion.

In 2011 we received 130 nominations for our feature. That year, we featured women impacting the industry around the world, a theme we continued in 2012. Last year we also added standouts from contract research organizations, which have been key players in the evolution of pharma R&D.

This year, we're looking for those who exemplify success through their achievements and inspire others.

Submit your nominations now for the 2013 report featuring the fiercest women in biotech.

-- Jennifer Levin (email | Twitter)

Suggested Articles

It’s been a minute, but AstraZeneca has gotten the FDA’s all-clear to restart the U.S. study of its COVID-19 vaccine.

Combining KSQ's USP1 inhibitor with Merck and AstraZeneca's PARP inhibitor Lynparza was more effective in animal models than either drug on its own.

Solid Bio is teaming up with Ultragenyx on Duchenne muscular dystrophy in a deal worth $40 million upfront but could net it another $255 million.